US 12,168,144 B2
Light therapy system and methods of use
Jes Broeng, Birkeroed (DK); Paul Michael Petersen, Hilleroed (DK); Ngoc Mai Thi Nguyen, San Jose, CA (US); and Lance Kriegsfeld, Berkeley, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US); and Danmarks Tekniske Universitet, Kongens Lyngby (DK)
Filed by The Regents of the University of California, Oakland, CA (US); and Danmarks Tekniske Universitet, Kgs. Lyngby (DK)
Filed on Jul. 13, 2022, as Appl. No. 17/864,281.
Application 17/864,281 is a continuation of application No. 16/775,131, filed on Jan. 28, 2020, granted, now 11,433,253.
Application 16/775,131 is a continuation of application No. 16/486,136, granted, now 11,813,475, previously published as PCT/US2018/018250, filed on Feb. 14, 2018.
Claims priority of provisional application 62/595,065, filed on Dec. 5, 2017.
Claims priority of provisional application 62/459,138, filed on Feb. 15, 2017.
Prior Publication US 2023/0084974 A1, Mar. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 5/06 (2006.01)
CPC A61N 5/0618 (2013.01) [A61N 5/0622 (2013.01); A61N 2005/0651 (2013.01); A61N 2005/0663 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating a subject having a neurodegenerative condition, said method comprising:
exposing said subject to light produced by alternately blinking a first light source and a second light source,
where the first light source produces a blinking first light, where the first light comprises a blue spectral component,
where the second light source produces a blinking second light lacking the blue spectral component or where the blue spectral component of said second light is smaller than the blue spectral component of the first light,
where the first light and the second light have substantially the same luminance, where the blinking of the first light and the second light is at a frequency ranging from 20 Hz up to 60 Hz, at an intensity and duration sufficient to mitigate a symptom of said neurodegenerative condition, or to slow or stop the progression of said neurodegenerative condition; and
where the second light supplements the first light so that the blinking of said first light when combined with the second light from said second light source is substantially undetectable by said subject.